CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new treatment for non-small cell lung cancer with KEAP1 mutations by targeting its unique metabolic vulnerabilities. The research identifies a specific transporter involved in sulfite export and introduces SulfExstatin1, a small molecule inhibitor that selectively disrupts this proc…
Non-small cell lung cancer (NSCLC) harboring KEAP1 mutations is associated with a poor prognosis and resistance to conventional therapies.
However, KEAP1/NRF2 dysregulation induces metabolic reprogramming, which can be exploited for therapeutic benefit.
Our research has uncovered that these cells produce and accumulate high levels of sulfur-containing compounds, a metabolic vulnerability in these cancer cells.
To maintain cellular homeostasis and survival, these cells rely on the active export o…
JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
